Compare Norfolk Southern Corporation (NSC) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Norfolk Southern Corporation vs TransMedics Group Inc — how do they compare? Norfolk Southern Corporation trades at $323.3 (market cap $72.62B), while TransMedics Group Inc trades at $86.4 (market cap $3.00B). The key difference: Norfolk Southern Corporation is far larger — about 24.2× TransMedics Group Inc's market cap, and Norfolk Southern Corporation pays a 1.67% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals.
| NSC | TMDX | |
|---|---|---|
Market Cap | $72.62B | $3.00B |
Sector | Technology | Technology |
52-Week High | $352.98 | $150.42 |
52-Week Low | $272.36 | $61.99 |
Enterprise Value | $88.16B | $3.39B |
Dividend Yield | 1.67% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Norfolk Southern (NSC) trades at $327.92, down 0.47% on the day, amid a bearish technical signal. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results pending. Key fundamentals show strong profitability with a 21.02% net income margin and 16.97% ROE, though valuation multiples like the P/E of 27.98 appear elevated. Recent news highlights ongoing institutional accumulation and progress in the proposed merger with Union Pacific, which remains under regulatory review.
The outlook is balanced; the merger potential offers upside, but regulatory hurdles and a premium valuation pose risks. Analyst consensus is mixed with a Hold rating predominating, though the $369.67 price target implies modest upside. Earnings sustainability and merger approval are critical for near-term direction.
TransMedics Group (TMDX) trades at $88.27, down 1.9% on the day, with a bullish technical signal from moving averages but mixed earnings results. The company reported strong revenue growth to $605.49M in 2025, with a net income margin of 22.69%, though profitability is expected to moderate in 2026. Recent news highlights ongoing legal investigations into fiduciary duties alongside positive coverage of growth initiatives in kidney transplantation and European expansion.
The stock presents a growth opportunity with analyst consensus pointing to a $99.57 price target, but risks include margin pressure from heavy investments and legal uncertainties. Earnings misses in recent quarters and a projected decline in net income for 2026 warrant caution, though institutional interest remains with a bullish rating from 69% of analysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Norfolk Southern Corporation
Norfolk Southern Corporation is a major North American railroad company operating one of the largest freight rail networks in the eastern United States. The company transports a diverse range of commodities, including coal, intermodal containers, and various industrial products. NSC is a critical link in the nation's supply chain, providing efficient, long-haul transportation services to and from ports and industrial centers.
Read more on NSC →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
